Business Context and Reporting Period
This Form 8-K was filed by AlloVir, Inc. (not Kalaris Therapeutics, Inc.) on February 12, 2024, reporting an event that occurred on February 9, 2024. The company is a biopharmaceutical firm incorporated in Delaware, with its common stock (Symbol: ALVR) listed on the Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report regarding a listing status notice and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material change reported is a regulatory compliance issue with the Nasdaq Stock Market:
- Non-Compliance: AlloVir received notice that its common stock closing bid price was below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
- Immediate Effect: The notice has no immediate effect on the listing; the stock continues to trade under the symbol "ALVR."
Outlook, Risks, and Management Commentary
Compliance Period: AlloVir has been granted an initial 180-calendar day period, ending August 7, 2024, to regain compliance. To meet the standard, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days within this window.
Future Options: If compliance is not achieved by August 7, 2024, the company may be eligible for a second 180-day period if certain requirements are met. Management is currently evaluating options to regain compliance, which could include a reverse stock split.
Risks: Failure to regain compliance within the allotted timeframes could result in the delisting of the company's common stock from the Nasdaq Global Select Market.
Investor Verification Checklist
- Verify the current closing bid price of ALVR to assess proximity to the $1.00 threshold.
- Monitor upcoming announcements regarding the potential implementation of a reverse stock split.
- Review the company's most recent 10-K or 10-Q filings for actual financial health metrics (cash runway, burn rate) not included in this 8-K.
- Confirm the exact date of the 10-day compliance window if the stock price rises above $1.00.